QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

RAPP

QT61Rapport Therapeutics, Inc. Common Stock
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
37.34
+0.47+1.27%
OverviewShort InterestFilings
RAPPQT61Rapport Therapeutics, Inc. Common Stock·NASDAQ
OverviewShort InterestFilings
37.34+1.27%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own18.64%
Shs Outstand47.83M
Perf Week6.05%
Market Cap1.35BForward P/E-EPS next Y-4.33Insider Trans-1.99%Shs Float-Perf Month8.64%
Enterprise Value1.28BPEG1.01EPS next Q-0.87Inst Own-Short Float-Perf Quarter35.98%
Income-82893098.00P/S67.28EPS this Y-Inst Trans-Short Ratio-Perf Half Y21.39%
Sales20.00MP/B3.69EPS next Y-28.70%ROA-21.56%Short Interest-Perf YTD23.07%
Book/sh9.87P/C-EPS next 5Y-ROE-24.79%52W High42.27 -11.66%Perf Year241.00%
Cash/sh9.97P/FCF-EPS past 3/5Y-ROIC-25.34%52W Low10.51 255.28%Perf 3Y-
Dividend Est.-EV/EBITDA-10.82Sales past 3/5Y-Gross Margin95.00%Volatility4.14% 3.85%Perf 5Y-
Dividend TTM-EV/Sales63.92EPS Y/Y TTM31.22%Oper. Margin-611.03%ATR (14)2.29Perf 10Y-
Dividend Ex-Date-Quick Ratio27.08Sales Y/Y TTM-Profit Margin-536.38%RSI (14)51.74Recom1.75
Dividend Gr. 3/5Y-Current Ratio27.08EPS Q/Q38.24%SMA20-0.10%Beta1.67Target Price57.50
Payout0.00%Debt/Eq0.02Sales Q/Q-SMA501.70%Rel Volume1.06Prev Close36.87
Employees69LT Debt/Eq0.02EarningsAug 06SMA20024.86%Avg Volume333.91KPrice37.34
IPO DateJun 07, 2024Option/ShortYes / YesEPS/Sales Surpr.25.00% 150.00%Net Debt/EBITDA0.57Volume355,436Change1.27%
Analyst Ratings
DateActionAnalystRatingTarget
May-21-26ReiteratedBTIGBuy$47 → $65
May-18-26ReiteratedTruist Financial$44 → $56
Apr-10-26InitiatedRaymond JamesStrong Buy$66
Feb-02-26InitiatedWells FargoOverweight$51 → $43
Dec-19-25ReiteratedWells Fargo$51
Dec-09-25ReiteratedH.C. Wainwright$34 → $40
Sep-16-25InitiatedTruistBuy$44
Jul-02-24InitiatedJefferiesBuy$35
Jul-02-24ReiteratedStifel Nicolaus$35
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A110
Gross Profit-1-10
Selling, General and Administrative Excl. Other30228
Research and Development956128
Other Operating Expense0-10
Operating Income-125-83-36
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)0-5-1
Net Income Before Taxes-111-78-35
Income Taxes
000
Consolidated Net Income-111-78-35
Net Income From Continuing Operations-111-78-35
Net Income-111-78-35
EPS (Recurring)-2.86-3.78-0.95
EPS (Basic, Before Extraordinaries)-2.86-3.78-0.95
EPS (Diluted)-2.86-3.78-0.95
EBITDA-124-77-35
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding472118
Market Capitalization1,426——
Operating Lease Expense
———
Insider Trading Volume
$39.20$35.28$31.35$27.43$23.51● Close Price0.00M4.67M9.35M14.02M18.69MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Third Rock Ventures V, L.P.10% OwnerMay 26 '26Sale40.0518,572743,7536,280,525May 28 12:00 AM
Third Rock Ventures V, L.P.10% OwnerMay 11 '26Sale40.24133,6185,377,3236,299,097May 13 12:00 AM
Third Rock Ventures V, L.P.10% OwnerMay 08 '26Sale40.315,018202,2566,432,715May 11 12:00 AM
Third Rock Ventures V, L.P.10% OwnerMay 07 '26Sale40.12271,49510,892,6516,437,733May 11 12:00 AM
Third Rock Ventures V, L.P.10% OwnerApr 17 '26Sale40.32426,00517,175,2446,709,228Apr 21 12:00 AM
Yeleswaram KrishnaswamyChief Development OfficerApr 17 '26Sale39.9920,225808,844246,426Apr 21 12:00 AM
Yeleswaram KrishnaswamyChief Development OfficerApr 14 '26Sale35.0810,200357,797266,651Apr 14 12:00 AM
Yeleswaram KrishnaswamyChief Development OfficerApr 13 '26Sale34.979,165320,537276,851Apr 14 12:00 AM
Yeleswaram KrishnaswamyChief Development OfficerApr 10 '26Sale34.9850017,490286,016Apr 14 12:00 AM
Yeleswaram KrishnaswamyChief Development OfficerApr 08 '26Sale34.9036012,564286,516Apr 09 12:00 AM
Gault CherylChief Operating OfficerMar 30 '26Sale28.1910,000281,857159,914Mar 31 12:00 AM
Yeleswaram KrishnaswamyChief Development OfficerMar 25 '26Sale29.9910,115303,355286,876Mar 26 12:00 AM
Gault CherylChief Operating OfficerMar 05 '26Sale28.932,01458,265169,914Mar 09 12:00 AM
Bredt DavidChief Scientific OfficerFeb 19 '26Option Exercise1.8012,00021,600393,075Feb 19 12:00 AM
Ceesay AbrahamChief Executive OfficerFeb 18 '26Sale29.3510,916320,37320,729Feb 19 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR